Alternative administration routes and delivery technologies for polio vaccines. by Kraan, H. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ierv20
Download by: [Universiteit Leiden / LUMC] Date: 27 September 2016, At: 04:34
Expert Review of Vaccines
ISSN: 1476-0584 (Print) 1744-8395 (Online) Journal homepage: http://www.tandfonline.com/loi/ierv20
Alternative administration routes and delivery
technologies for polio vaccines
Heleen Kraan, Wanda van der Stel, Gideon Kersten & Jean-Pierre Amorij
To cite this article: Heleen Kraan, Wanda van der Stel, Gideon Kersten & Jean-Pierre Amorij
(2016) Alternative administration routes and delivery technologies for polio vaccines, Expert
Review of Vaccines, 15:8, 1029-1040, DOI: 10.1586/14760584.2016.1158650
To link to this article:  http://dx.doi.org/10.1586/14760584.2016.1158650
Accepted author version posted online: 25
Feb 2016.
Published online: 16 Mar 2016.
Submit your article to this journal 
Article views: 99
View related articles 
View Crossmark data
REVIEW
Alternative administration routes and delivery technologies for polio vaccines
Heleen Kraana, Wanda van der Stelb, Gideon Kerstena,b and Jean-Pierre Amorija
aDepartment of Research, Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands; bDivision of Drug Delivery Technology,
Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands
ABSTRACT
Global polio eradication is closer than ever. Replacement of the live attenuated oral poliovirus vaccine
(OPV) by inactivated poliovirus vaccine (IPV) is recommended to achieve complete eradication. Limited
global production capacity and relatively high IPV costs compared to OPV spur the need for improved
polio vaccines. The target product profile of these vaccines includes not only dose sparing but also high
stability, which is important for stockpiling, and easy application important for (emergency) vaccination
campaigns. In this review, the current status of alternative polio vaccine delivery strategies is given.
Furthermore, we discuss the feasibility of these strategies by highlighting challenges, hurdles to over-
come, and formulation issues relevant for optimal vaccine delivery.
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Introduction
Poliomyelitis is an infectious disease caused by poliovirus, an
enterovirus belonging to the Picornaviridae family. After infec-
tion by one of the three serotypes, the virus multiplies in the
intestine from where it can invade the nervous system and
cause paralysis.
The only way to combat poliomyelitis is by prevention
through vaccination. Most industrialized countries use triva-
lent inactivated poliovirus vaccine (IPV, based on the wild
polio ‘Salk’ strains) in their pediatric vaccination programs.
IPV may be formulated as a combination vaccine with other
antigens, such as diphtheria/tetanus/(acellular) pertussis,
Haemophilus influenzae type B, and hepatitis B surface antigen.
In developing countries, the live attenuated oral poliovirus
vaccine (OPV, based on Sabin strains) has been the vaccine
of choice because of a number of advantages as compared to
IPV. These include the induction of stronger mucosal immu-
nity, ability to interrupt wild poliovirus circulation in areas of
intense fecal–oral transmission, immunization of close con-
tacts through secondary spread, affordability, and ease of
administration. However, the use of OPV comes with a rare,
but serious adverse effects, that is reversion to virulence
resulting in vaccine-associated paralytic polio (VAPP).
Circulating reverted vaccine viruses (circulating vaccine-
derived polioviruses), may have similar transmissibility and
neurovirulence as wild poliovirus and can cause new polio
outbreaks.
The eradication of polio is one of the top global health
priorities. Efforts to eradicate polio should focus on both wild
polioviruses as well as vaccine-derived viruses. Therefore, the
Global Polio Eradication Initiative (GPEI) has defined an end-
game strategy that includes a phased withdrawal of OPV and
the worldwide inclusion of IPV into all routine immunization
programs [1]. Besides the short-term changes in current immu-
nization procedures, more affordable, more effective, and safer
forms of the existing polio vaccines are needed [2]. The target
product profile of the ideal polio vaccine may differ depend-
ing on the eradication phase (Table 1). In the development of
new polio vaccine delivery systems, the intended use is an
important consideration.
In the short term, the worldwide switch to injected IPV at
the expense of OPV will occur, which brings some challenges:
(1) IPV is injected and so has the disadvantages of needles
and syringes, like risk of needle stick injuries, potential
reuse of needles, and, as a result, complicated waste
management.
(2) IPV is, compared to OPV, considerably more expensive. The
downstream processing is more complex since the parent-
eral version is extensively purified. Besides, unlike OPV, the
inactivated virus is not able to replicate in the host. The
dose needed to confer protection is about 10 times higher.
(3) In general, IPV does not induce mucosal intestinal immu-
nity (polio-specific secretory IgA (sIgA) antibodies), which
is crucial to provoke a strong herd immunity effect and to
interrupt poliovirus transmission in developing countries.
Although IPV can prevent poliovirus outbreaks and pro-
vide herd protection to some extent, IPV is probably less
effective to stop transmission of poliovirus.
A disadvantage of both OPV and IPV is that they need a cold-
chain for their storage and logistics. For use in emergency
vaccinations or post-eradication stockpiling this is undesir-
able. Stockpiling after eradication and cessation of routine
polio vaccination is important in case of reemergence of the
virus.
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The GPEI is pursuing some priority approaches to make IPV
more affordable for low-income countries, like dose-sparing
strategies using adjuvants and the introduction of IPV based
on Sabin strains, instead of wild type poliovirus (Salk) strains
[2]. An overview of different approaches that are currently
under development, including their strengths and weak-
nesses, is given in Figure 1.
The current review will focus on IPV delivery approaches by
highlighting recent developments of alternative administra-
tion methods for IPV. The uses of dermal delivery of polio
vaccines, like jet-injection and microneedle approaches, are
discussed. Mucosal delivery and the potential of new mucosal
delivery routes for IPV are described. Finally, future perspec-
tives, including the potential of improved vaccine formula-
tions, the use of adjuvants, and promising delivery
technologies, are given.
Novel intramuscular and subcutaneous
administration
Most of high-income countries use Salk IPV, which is adminis-
tered intramuscularly, in their routine vaccination programs,
often in combination with other antigens. Alternative delivery
approaches are developed for polio vaccination. These vaccine
Table 1. The ideal polio vaccine is not able to revert to virulence, is stable during storage, affordable, easy to produce, and induces sterilizing immunity (i.e.
interrupts virus transmission).
Polio status OPV/IPV in use IPV only used Post polio eradication Post vaccination
Purpose
Routine
vaccination Outbreak control
Routine
vaccination Outbreak control
Routine
vaccination Outbreak control Outbreak control
Product attribute
No reversion to virulence − − + + ++ ++ ++
Transmission
interrupting
0 ++ 0 + − ++ ++
Stable 0 + + + + ++ ++
Affordable + 0 ++ 0 ++ 0 0
Easy to administer 0 ++ 0 ++ ++ + +
Easy to produce − − − − − ++ ++
Safe to produce + + + + ++ ++ ++
The relevance of this ideal target product profile depends on the polio status worldwide (i.e. current phase with OPV/IPV in use, after complete OPV cessation, post-
eradication, or, eventually, without routine polio vaccination), but also on the aim (i.e. routine immunization program vs. outbreak control campaigns).
−: less important; 0: neutral; +: important; ++: very important; IPV: inactivated poliovirus vaccine; OPV: oral poliovirus vaccine
Figure 1. An overview of different approaches, which are currently under development, to make inactivated poliovirus (IPV) more affordable for low-income
countries.
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delivery strategies could address issues, like safety, needle
phobia, and vaccine stability.
Needle-free (intramuscular/subcutaneous) jet injection
An option to facilitate intramuscular (IM) or subcutaneous
(SC) delivery is the use of needle-free jet injectors. Jet injec-
tors use high pressure to inject the fluid into or through the
skin, either subcutaneously or intramuscularly. Injection
depth depends on nozzle design, pressure, and pressure
profile during injection. Initial studies aimed at demonstrat-
ing non-inferiority or superiority of IM jet injections over the
needle-based IM vaccinations. The study of Lipson et al.
demonstrated that IPV vaccinations using the press-o-jet
[3] induced similar responses in children as the needle
approach [4]. In general, the use of jet injectors could pro-
vide a solution for safety issues accompanied with needles,
reduces the amount of waste, and increases the immuniza-
tion speed. However, after the introduction of the devices,
concerns about blood-borne infection were raised. The use
of multidose systems with the same nozzle, occasionally lead
to transmission of for example Hepatitis B between recipi-
ents. Studies demonstrated the infectious potential of sev-
eral jet injectors [5,6]. Today, safe jet-injection systems are
available using disposable parts facing the vaccinee. Current
systems in use for IM and SC administration of vaccines are
the Biojector2000 (Bioject Medical Technologies Inc., Tigard,
OR, United States), ZetaJet (Bioject Medical Technologies
Inc., Tigard, OR, United States), and PharmaJet (PharmaJet,
Golden, CO, United States).
Soonawala et al. compared the PharmaJet with conven-
tional needle injection (one IPV dose) in healthy adults in a
phase 1 study [7]. Vaccination with the jet injector was less
painful (87% no pain) than vaccination with needle and
syringe (60% no pain), but caused more adverse effects at
the site of administration, like transient erythema and
swelling. Moreover, IM jet injector vaccination resulted in
similar geometric mean virus-neutralizing antibody titers as
induced after IM injection using needle and syringe. These
data demonstrated that the technique itself could help to
improve acceptability by reducing the pain sensation [7].
Intradermal (ID) jet injection further reduced pain and
increased immunogenicity as further described in the ‘Jet
injector’ section. Since subjects had background immunity
against polio in this phase 1 study, further clinical testing
(phase 2 and 3) is needed to assess immunogenicity.
A recently completed trial in a large cohort of infants in
Gambia addresses safety and immunogenicity of IPV given
concomitantly with other vaccines (Measles, Rubella, and
Yellow Fever) (study nr. NCT01847872). One of the aims of
this trial was to compare the performance of a jet injector
with that of needle and syringe for IM and ID delivery.
Seroconversion levels, adverse events, cellular immune
responses, and virus shedding after OPV ‘challenge’ are mea-
sured to quantify the type of response induced and the
potential presence of mucosal immunity. The results have
not been published yet.
Bioneedles
Bioneedles are dissolvable implants (12 mm) made from bio-
degradable polymers that can be filled with antigen and are
injected subcutaneously by air pressure. The included vaccine
formulation is in a solid state. Using a solid formulation could
diminish the dependence on the cold-chain. Furthermore, the
Bioneedles could eliminate needle-stick accidents and do not
create sharp waste.
IPV formulated in Bioneedles showed improved thermostabil-
ity compared with liquid IPV [8]. Storage of the IPV-filled
Bioneedles at 45°C for 1 week led to a reduction of antigenicity
between 20% and 50% for the different serotypes compared to
80–100% antigen loss for the standard liquid form. Storage of the
liquid vaccine at 60°C for 1 h did lead to complete loss of antigen
compared to 20–30% reduction for the antigen in Bioneedles.
Furthermore, vaccination of rats with IPV Bioneedles-induced
comparable levels of virus-neutralizing antibodies to the IM
administered conventional IPV vaccine. These data demonstrate
that the Bioneedle polio vaccine has similar immunogenic prop-
erties and better resistance to higher temperatures compared to
current liquid IPV. The implementation of the thermostable vac-
cine in biodegradable needles could help to stimulate the expan-
sion of IPV usage to developing countries, because of its
improved thermostability, which is required in remote areas,
and potential to vaccinate relatively fast.
Dermal immunization
The dermis and epidermis of the human skin are rich in
antigen-presenting cells (APC) and therefore are attractive
sites for vaccine delivery. The skin’s structural and cellular
composition enables it to function as a physical and immuno-
logical barrier, suggesting that delivery of vaccines to the
dermal layers, rather than IM or SC vaccine delivery, could be
more efficient and induce protective immune responses with
smaller amounts of vaccine antigen [9].
Dendritic cells (DCs) are APCs that serve to efficiently
amplify innate and adaptive immune responses. In the normal
human skin, two distinct populations of immature DCs are
found, each within a specific layer, that is Langerhans cells
(LCs) in the epidermis and dermal DCs in the deeper skin
layers [10]. However, the skin is equipped with an impressive
barrier, the stratum corneum, which makes it almost impossi-
ble to induce an immune response through dermal vaccina-
tion without disrupting this first defense line. Therefore,
effective, safe, and convenient methods to achieve disruption
of the stratum corneum are needed [11].
The ID delivery methods that are currently available can be
roughly classified into three categories: administration by (1) nee-
dle and syringe, (2) jet injectors, and (3) microneedles [12]. An
overview of these different ID delivery methods tested in combi-
nation with IPV is given in Tables 2 (preclinical) and 3 (clinical).
Traditional needle-based dermal vaccination
The traditional needle-based ID vaccines rely on a single nee-
dle inserted shallow into the skin (the ‘Mantoux’ technique,
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originally used as diagnostic for tuberculosis) or needle(s)
especially designed to penetrate only into the dermis (i.e.
bifurcated needles, multipuncture systems). They have been
used extensively in the past for various vaccination programs,
like those for smallpox, and some are studied for the use in
the polio immunization programs. However, ID-injection
methods using needles and syringes require considerable
expertise and are, therefore, not ideal for routine vaccinations.
Although IPV is given intramuscularly, the initial experi-
ments of Jonas Salk anticipated its use via the ID route. In
1953, Salk demonstrated the immunogenicity of IPV admini-
strated both intramuscularly and intradermally [28]. Despite
these and more promising results in the mid-1950s [28–31],
the ID route was only in Denmark the most used route for IPV
vaccination at that time [31,32].
With the purpose of developing a more affordable IPV for
the lower income countries and increase its use in the post-
eradication era, different studies investigated ID polio vaccina-
tion [33]. After development and licensure of the enhanced-
potency IPV, which was responsible for highly improved ser-
oconversion rates for all three serotypes due to its higher
content of poliovirus antigen [34], three trials using ID admin-
istration of the IPV have been conducted in India since the
early 1990s. Those proof-of-concept studies established the
immunogenicity of a fractional (one-fifth) IPV dose delivered
ID (via Mantoux injection) in subjects who had been pre-
viously immunized [35], or had never been immunized against
polio [36]. The trial among 69 Indian infants demonstrated
that 2 or 3 fractional doses ID were equivalent in terms of
seroconversion to 2 full doses of IPV delivered IM or 5 doses of
OPV (based on historical data). All infants who had no preex-
isting maternal antibodies, seroconverted to all serotypes [20].
In none of these studies, however, a comparator IM group was
included. Therefore, a randomized-controlled trial was con-
ducted in the Philippines, to compare the primary and booster
immunogenicity of IPV by ID injection (one-fifth dose) with the
IM route (full dose). These data demonstrated non-inferiority
of fractional dosing by the ID route, and thus confirmed the
validity of this IPV vaccination strategy [24].
The bifurcated needle and multipuncture system were
introduced to improve ID delivery of vaccines by limiting the
penetration depth, which ensures dermal delivery. The bifur-
cated needle consists of a needle that branches out into two-
solid needle points. Formulations are administered via multi-
ple punctures at a local area. To our knowledge, no research
has been conducted with this type of needle administer-
ing IPV.
The multipuncture system was deployed for Bacillus
Calmette–Guerin (anti-tuberculosis) vaccines. The vaccine
administration is a two-step process. First, the skin is pene-
trated using a device with multiple needles. Second, the vac-
cine is applied evenly on the punctured area. A large clinical
trial conducted in Cuba included the multipuncture system as
a control in a comparative study for three needle-free delivery
devices for polio vaccination. In this study, inferior immune
responses (defined as seroconversion and increase in virus-
neutralizing titers) following fractional-IPV dose administered
via the ID route compared with full-dose IPV administered IM
were reported [26].
Considered together, the trials in the Philippines (Mantoux
injection) [24] and Cuba (multipuncture system) [26] provided
inconclusive results after ID delivery of IPV. Moreover, a pro-
blem for traditional needle-based methods is their inaccuracy,
the need of well-trained personal for administration, and low-
patient compliance. To be able to completely use the potential
of the skin as a vaccination site, less invasive systems are
examined in animal and human trials.
Jet injector
While several studies confirm the observations of Salk about
the potential of dose sparing by ID injection, usage of needle
Table 2. Pre-clinical assessment of other administration routes than conventional intramuscular (IM) or subcutaneous (SC) injection for polio vaccination.
Delivery method
IPV dose (DU) T1;
T2;T3 Adjuvant
Animal
model Immune response Ref.
Novel IM/SC delivery
Bioneedle 2.7;0.6;2.1 PagLa Rats Inferior VN titers for type 3 after prime immunization for Bioneedle-group. Similar VN
titers for all serotypes after booster regime
[8]
Intradermal
ID injection (Unclear) CAF01b Mice Similar (type 1 and 3) or superior VN titers after ID vaccination plus adjuvant and
superior IgG titers compared to IM injection
No mucosal IgA (feces)
[13]
ID injection 1–10;1–10;1–10 dmLT Mice Similar VN titers and superior polio-specific IgG titers compared to IM vaccination
Prolonged systemic immunity (VN)
Mucosal type 1- and 2-specfic IgA titers (feces and PP)
[14]
Microneedles (hollow) 5/15;NA;NA NA Rats Polio-specific IgG and VN titers similar to IM and ID vaccination using needle/syringe [15]
Microneedles (hollow;
Micronjet600)
2–40;0.4–8;1.6–32
(5–100% of shd)
NA Rats Superior VN titers for 40% ID with 40% IM and when comparing 40% ID with 100% IM
(49 days)
[16]
Microneedles (coated) 47;9;38 NA Monkeys VN titers similar to IM injection for type 1 and 2, but inferior VN titers for type 3 [17]
Microneedles (coated) 45;NA;NA TMC Rats Inferior polio-specific systemic IgG titers compared to IM or ID injection [18]
Mucosal (sublingual)
Thermoresponsive gels 1.34;0.3;1.1
6.5;1.5;5.5
dmLT Mice No immune responses detected without adjuvant. Inferior VN titers or systemic Ig titers
compared to IM injection.
Superior mucosal IgA titers (feces, saliva) for SL vaccination (+adjuvant) compared to
IM injection
[19]
DU: D-antigen unit; dmLT: double mutant heat-labile toxin; ID: intradermal; IM: intramuscular; IPV: inactivated poliovirus vaccine; NA: not applicated; SL: sublingual;
T1/2/3: serotype 1/2/3; TMC: trimethyl chitosan; VN: virus-neutralizing.
aPagL LPS is an LPS-derivate obtained through expression of the Bordetella bronchiseptica PagL gene in Neisseria meningitides LPS.
CAF01 is an adjuvant composed of cationic liposomes DDA (dimethyldioctadecylammonium) and TDB (trehalose 6,6′-dibehenate).
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ID injections on a large scale is not foreseeable given that the
need for skilled personnel, which is a major limitation for
large-scale campaigns, and the safety and disposal concerns
related to the use of needles remain. To overcome these
problems and increase the affordability of IPV, needle-free
devices for ID injection, which can be manually reset and
used by volunteers, if necessary, have been developed [37].
Needle-free jet injector systems are used for IM and SC
administration (see the ‘Needle-free (intramuscular/subcuta-
neous) jet injection’ section), but are also studied as ID deliv-
ery devices (e.g. Biojector 2000, PharmaJet). Furthermore, the
ID Pen injector (Bioject Medical Technologies Inc., Tigard, OR,
United States) and the PharmaJet Tropis (PharmaJet, Golden,
CO, United States) are especially designed for the ID delivery
of vaccines. Several clinical trials with polio vaccines are
already conducted to compare the different injector systems
to IM (conventional) hypodermic needles or to each other
(Table 3).The Biojector 2000, a disposable syringe jet injector
for ID delivery, has been evaluated by WHO sponsored studies
in Cuba and Oman and compared to IM delivery using con-
ventional syringe and needle. Two different IPV vaccines and
two different immunization schedules were evaluated. Target
groups were infants in both studies. The primary objective of
these trials was to demonstrate non-inferiority of fractional
(one-fifth) dose in terms of seroconversion for the ID route
compared to the full dose via the IM route. Non-inferiority
could not be demonstrated in the Cuban study; significantly
lower seroconversion rates (ID: 52.9%, 85.0%, and 69.0% vs. IM:
89.3%, 95.5%, and 98.9% for serotypes 1, 2, and 3, respectively)
and significant lower median antibody titers were induced in
the ID arm after three doses of IPV [22]. In the Omani study,
similar levels of seroconversion for serotypes 1 and 3 were
after ID delivery of fractional doses and after IM vaccination of
the full dose were detected. Serotype 2 showed a statistically
significant different, although small, reduction in seroconver-
sion rate after ID delivery (ID: 95.7% vs. IM: 100%). For all
serotypes, the median antibody titers were significantly
lower in the fractional dose group [21], but it remains unclear
whether the differences have practical implications since any
detectable titer of neutralizing antibody against poliovirus
would be expected to prevent against paralytic disease [38].
Maternal antibodies may interfere with IPV vaccination at very
young age [39,40]. Administration of fractional doses of IPV is
unlikely to serve as an optimal antigen-sparing strategy when
given at the standard ages of 6, 10, and 14 weeks, rather than
a schedule in which the first dose is administered at 2 months
of age [21,22].
Dermal IPV vaccination with the PharmaJet device has
been evaluated in clinical trials in India and The
Netherlands [7,21]. The study in The Netherlands was per-
formed administering vaccine to young adults, whereas the
study in India was conducted with infants. For the Indian
study, the ID administered fractional dose was less effective
than full-dose IM administration in seroconverting seronega-
tive infants and in increasing antibody titers in seropositive
children. This result is in contrast with the very small differ-
ences found between fractional and full-dose in a 3-dose
schedule conducted in Oman (as described above) [21],
which might be related to the device and/or geographic
differences. Unfortunately, as with most studies mainly aim-
ing at non-inferiority of ID fractional dose IPV delivery, the
study was not designed to evaluate the impact of ID-admin-
istration solely, for example by including a group that
receives fractional dose by IM injection as performed in
the Dutch study [7].
More recently, in another WHO-sponsored clinical trial in
Cuba, the performance of three jet injectors, that is
Biojector2000, Bioject ID Pen injector, and PharmaJet Tropis,
was evaluated and the immune response induced by a ID
administered fractional dose with that induced by full-dose
IPV given via the IM route [26]. Children between 12 and
20 months of age, who had previously received 2 doses of
OPV, received a single dose of IPV either full-dose IPV via IM
injection or fractional dose given via the ID route using one of
the jet injectors or via ‘Mantoux’ needle and syringe. Whereas
the Indian study reported excellent immunogenicity of frac-
tional IPV when administered in a three-dose schedule with
appropriate age and interval between doses [21], the results
from recent Cuban study were more comparable with to those
from the boosting study in India were fractional IPV also
induced significantly lower immune responses than full-dose
IPV [26]. Nevertheless, at the end of the study, the seroposi-
tivity rates were similar for both ID jet injector, ‘Mantoux’
needle and syringe (ID), and conventional IM-injection groups
[26].
The fractional dose strategy might be suitable as a substi-
tute to full-dose IPV when given at the correct interval. The
newly developed jet injector (Tropis Needle-Free Injector from
PharmaJet) would facilitate the administration of a fractional
dose when given ID [26]. The use of jet injectors may solve
two existing problems of IPV by being safer to administer and
decreasing costs by using less antigen. In addition, it has been
hypothesized that ID delivery could improve protection
against infection in the gut, since it may stimulate IgA mucosal
immunity [41]. However, further investigations are needed to
assess whether the lower immunogenicity of fractional IPV is
sufficient to provide adequate protection and whether poten-
tial loss of immunogenicity is worth the cost savings.
Microneedle approaches
Another approach for ID vaccine delivery makes use of micro-
needle arrays that can penetrate the stratum corneum. These
arrays are designed to disrupt the stratum corneum and target
LCs in the epidermis, but are minimally invasive, since the
nerves in the underlying tissue are not reached, and therefore
caused no pain and only minimal irritation [42]. Different
microneedle strategies are being exploited, that is the
straightforward methods by pretreating the skin with solid
microneedles followed by application of a vaccine containing
patch on the pretreated skin surface or using hollow micro-
needles to inject the vaccine into the epidermis. More recent
strategies include the use of dissolvable microneedles or anti-
gen-coated microneedle arrays. Microneedle technologies are
in preclinical or early clinical development and the optimal
microneedle strategy (material, shape) to deliver a vaccine into
the skin has not yet been established [11].
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Since ID administration of IPV has been shown to have
potential, a microneedle approach appears to be a useful
delivery method for IPV vaccination. To guarantee the stability
and immunogenicity of a dermal polio vaccine by using
coated or dissolvable microneedles, the development of a
solid IPV formulation is required, which is a major hurdle to
overcome. The problem of the often low loading capacity of
microneedle arrays may be solved by adjuvants (see the
‘Intradermal adjuvants’ section).
A preclinical study focusing on the production and usage of
a single hollow microneedle for IPV has been performed by
Van der Maaden et al. [18]. Immunization of rats with 5
D-antigen units of IPV serotype 1 at a depth of 300 µm led
to similar systemic IgG levels and virus neutralization titers as
compared to IM and needle-based ID injections [18]. One
other micro-injector system has been used for IPV vaccination:
the MicronJet600 (NanoPass Technologies Ltd., Rehovot,
Israel). The performance of the MicronJet600 in rats dosed
with a different fraction of the human IPV dose was studied
by Kouiavskaia et al. [16]. The response rate of animals immu-
nized with 20% or 40% of the human dose at 35 days was
equal for IM and ID injections. The 5% dose ID led to almost
double the response rate compared to IM injections. In addi-
tion, the neutralizing virus titer for type 1 and 3 after 35 days
and 40% of the full-dose was higher than full-dose adminis-
tered intramuscularly. These results confirmed the potential of
using fractional doses during ID vaccination programs. To
study the performance of the MicronJet600 in humans, a
large cohort of infants in Bangladesh was vaccinated with a
fractional IPV-dose. No adverse events were reported among
participants within 30 min after vaccine administration. None
of the adverse events reported during follow-up were attrib-
uted to the MicronJet600-device. When compared with full-
dose IPV given via IM injection, the fractional IPV dose given
ID by microneedles failed the non-inferiority test for all sero-
types for seroconversion observed with 1 or 2 doses [27]. In
this study, the assessment of the microneedle device was
limited to safety and injection quality. Therefore, the compar-
ison of immune responses induced by IPV administered by
MicronJet600 with standard needle and syringe for ID admin-
istration was not possible.
Apart from hollow microneedles, also solid needles for
skin pretreatment, biodegradable needles, and coated nee-
dles [43] are under development (Table 2). The usage and
action of both the solid- and hollow-needle arrays are simi-
lar to the single microneedle system. First of all, they
require the use of a delivery device like a pressure-based
applicator to actually puncture the skin. Second, the vaccine
is introduced from an external source, via a syringe into the
hollow needle or with a patch applying the vaccine onto
the punctured skin. The biodegradable and coated needles
are manufactured with the vaccine in or on top of the
needles and forced into the skin followed by release of
their content. Van der Maaden et al. developed a protocol
for the production of alternating layers of IPV and
N-trimethyl chitosan on microneedle arrays. Using a one-
layer coating technique, Edens et al. were able to create an
IPV-coated microneedle array that induced comparable neu-
tralizing antibody titers as IM injections [17].
Intradermal adjuvants
The necessity of adjuvants to stimulate systemic as well as
mucosal immunity has been reported in the preclinical dermal
immunization studies for Hepatitis B, HIV, Diphtheria, Cholera,
and ETEC diarrheal antigens. Two adjuvants have been studied
in combination with ID administration of IPV; CAF01 and
double mutant heat-labile toxin (dmLT) (Table 2).
CAF01 is a liposomal formulation composed of the cationic
lipid DDA (dimethyldioctadecylammonium) and TDB (treha-
lose-6,6-dibehenate). Dietrich et al. reported that IPV mixed
with CAF01 and administered to mice via ID injection, was
able to induce superior polio-specific serum IgG levels and
virus-neutralizing titers compared to the non-adjuvated vac-
cine [13]. No mucosal immunity (IgA in feces) was detected
after ID administration alone. However, simultaneous priming
of CAF01 adjuvated IPV at an ID and IM site followed by IM
boosting, induced significant levels of fecal IgA, without com-
promising serum virus-neutralizing titers [13].
Another study investigated the use of genetically detoxified
Escherichia coli heat-labile toxin (dmLT) as adjuvant for IPV
administered via IM or ID injection in mice [14]. Intradermal
vaccination with a fractional IPV-dose combined with dmLT as
adjuvant, elicited serum virus-neutralizing antibody titers simi-
lar to those obtained by non-adjuvated IPV given via IM
injection leading to a fivefold dose sparing. The duration of
the systemic antibody responses was prolonged for the mice
vaccinated with IPV adjuvated with dmLT either via IM or ID
delivery. Moreover, dmLT enhanced mucosal immunity as
defined by fecal and intestinal polio-specific IgA secretion,
when mixed with IPV and given IM or ID [13].
Mucosal immunization
Efficacy of mucosal vaccination
Although parenteral vaccination in some instances can pro-
vide protection against mucosal infections, in most cases and
especially in naïve subjects, for example newborns and young
infants, a mucosal vaccine delivery route is needed for effec-
tive immunization [44]. Despite the practical advantages of
mucosal vaccine delivery over injectable vaccines, only rela-
tively few vaccines for human use are licensed: oral vaccine
against cholera, typhoid, rotavirus, and polio, and a nasal
vaccine against influenza [45]. With the exception of the cho-
lera vaccines, which have a very strong intrinsic immunopo-
tentiating capacity [46], all these vaccines are live attenuated
vaccines. They effectively induce both systemic (serum) and
local mucosal immune responses, superior protection against
reinfection, persistence of immunological memory, better herd
immunity (because of secondary spread and mucosal immu-
nity), and are easy to administer [47]. For vaccination against
polio, polio-specific mucosal immunity in the gut is a powerful
protecting and transmission inhibiting mechanism as we know
from OPV. To date, marketed mucosal vaccines are adminis-
tered via the mucosa where protection is required. This is in
contrast to vaccination strategies that are under development
in order to generate mucosal immunity at distant effector
sites.
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OPV
The only marketed needle-free polio vaccine is the live atte-
nuated oral vaccine, OPV. The success of the live-attenuated
OPV is attributed to the capability of the virus to replicate in
the intestine, and thus generate an increasing antigen load
that elicits both strong systemic (serum IgG) and mucosal
(local sIgA) antibody responses [48,49] and long-term persis-
tence of neutralizing antibodies against poliovirus [50,51]. The
mucosal sIgA confers protection from poliovirus entry and
multiplication in the intestine [52].
Although OPV is the most effective vaccine in endemic and
high-risk areas to interrupt wild poliovirus transmission, the
estimated number of polio cases caused by OPV now likely
exceeds those related to wild polioviruses [53]. Wild type 2
poliovirus has not been detected since 1999 and the last case
of wild type 3 was reported in November 2012. For that
reason, the Endgame Strategy aims for global cessation of
type 2 OPV by switching from trivalent to bivalent OPV in
routine immunization programs [53]. Such bivalent vaccines
(type 1 and 3) are more immunogenic than trivalent OPV [54]
and nearly as effective as the monovalent OPV formulations,
especially in young children receiving their first polio immu-
nization [55–58]. However, the risks of VAPP and vaccine-
derived polioviruses by reversion of the Sabin strains to a
pathogenic strain still remain, and thus the global eradication
of polio by using these OPVs is impossible.
As a result, OPV cessation and replacement by IPV is highly
recommended and supported by the GPEI. Substitution of
OPV by a similar (low) dose oral IPV is unlikely to succeed.
Instead, the development of live poliovirus strains with stable
attenuation properties seems more feasible [59–61]. It is
expected that some of these approaches will be clinically
tested in the coming years.
Novel oral mucosal vaccine delivery – sublingual and
buccal route
Sublingual vaccine delivery has gained significant attention
during the past few years, as shown by the numerous pre-
clinical studies published in the last decade [62].
The use of the sublingual administration route for IPV has
been studied preclinically by White et al. [19]. They compared
the IM administration with sublingual administration using a
thermoresponsive gel (TRG) delivery system. These TRG sys-
tems are liquid at room temperatures and become solid in
warmer environments, like the mouth [63,64]. The solid gel
has high mucosal adhesion properties and ensures slow
release and potentially minimal loss because of swallowing.
The effect of dmLT as oral mucosal adjuvant was investigated
in this study as well. Sublingual administration of IPV without
dmLT or as liquid (instead of the TRG delivery system) was not
able to induce any immune response in mice. Sublingual
administered IPV as TRG in combination with dmLT led to
serum virus-neutralizing titers and systemic Ig levels, never-
theless significantly lower than when IPV alone is administered
via the IM route. However, the TRG-formulation containing IPV
plus dmLT induced systemic and mucosal IgA production, not
seen via IM vaccination. The mucosal immunity as measured
by IgA in salivary samples, improved with an increasing IPV
dose [19].
To our knowledge, the buccal route has not yet been
studied with IPV. Whether OPV administration leads to some
sublingual or buccal delivery or even replication is not known.
In order to achieve successful vaccination via the sublingual or
buccal route, enhanced vaccine formulations are essential to
target these mucosal inductive sites. It is expected that muco-
sal adjuvants and muco-adhesive agents to prolong contact
with the oral mucosa are needed [65].
Nasal vaccination and other novel mucosal vaccination
routes
Intranasal vaccination can avoid degradation of vaccine anti-
gen by digestive enzymes, low pH, and strong dilution. As a
result, nasal vaccination may require smaller doses of anti-
gen when compared to oral immunization [66]. However, for
nasal vaccination also, to date, no vaccine is on the market
on the basis of inactivated pathogens or subunits/proteins.
A risk of intranasal immunization is the possible deposition
of antigen or adjuvant in the central nervous system
through the olfactory bulbs and olfactory nerves, which
can cause adverse effects like temporary facial paralysis
(Bell’s palsy) [67,68]. This has been seen with a marketed
virosomal influenza vaccine that was adjuvated by heat
labile enterotoxin of E. coli (LT) and has been withdrawn
from the market due to this side effect. Also, wheezing may
occur in young children after intranasal vaccination. To date,
no efforts have been published that address nasal vaccina-
tion with polio vaccine formulations since this administra-
tion route induces mucosal immune responses mainly in the
respiratory and reproductive tract mucosae. Moreover,
immunization via the nose is often efficient for inducing
systemic immune responses, but not for eliciting intestinal
immunity in humans [69].
Other routes that are investigated for mucosal vaccination
against infectious diseases include pulmonary, vaginal, and
rectal routes [11]. However, like nasal vaccination, these routes
are not yet explored and/or disclosed for use in polio vaccina-
tion. Amongst others, this might be related to the fact that
these routes are not first choice because of ease of accessi-
bility, acceptance by the public, or technical challenges.
Mucosal adjuvants
The necessity of adjuvants to stimulate has been reported in
the preclinical mucosal immunization studies for several anti-
gens as reported elsewhere. In contrast to OPV and its poten-
tially live virus successors, mucosal polio vaccination based on
IPV is expected to require adjuvants in order to induce suffi-
cient systemic as well as mucosal immunity. Although there is
a broad preclinical experience on adjuvants for several anti-
gens as reported elsewhere [11], only limited studies have
shown the use of adjuvants for mucosal IPV delivery
(Table 2). Current experience is limited to the use of dmLT in
combination with TRG as described above.
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Expert commentary
Due to the cessation of OPV and the possible eradication of
polio there is a need for better and affordable IPV. Ideally, a new
generation of IPV should be administered through alternative
(needle-free) delivery routes, provide mucosal immunity, be safe
to manufacture, have a long shelf-life, be stable outside the
cold-chain, and be affordable for low-income countries.
Important variables for the development of improved IPV
are the route of administration, the selection of adjuvants, the
vaccine formulation, and the use of (non-invasive) delivery
methods [11]. The use of jet injectors is probably the fastest
way to introduce needle-free IPV vaccines, but apart from
injection safety, it may not lead to dose sparing. Another
promising and relatively short-term solution in the context of
parenteral IPV vaccination is probably the replacement of the
needle and syringe with a biodegradable implant as vaccine
carrier. Biodegradable implants could both reduce the safety
risks related to conventional injection and carries the vaccine
in the (more thermostable) solid form, which might minimize
the dependence on the cold-chain.
Mucosal vaccine delivery, like the sublingual and buccal
routes, has the potential to elicit local immune responses at the
point of virus entry, but often induces in the absence of an
adjuvant tolerance or low-to-undetectable immune responses
[70]. Therefore, efforts on mucosal vaccine design should focus
on (1) overcoming physiological barriers at mucosal routes, (2)
targeting local APCs for appropriate processing of the antigens
that lead to specific T- and B-cell activation, and (3) controlling
the kinetics of antigen and adjuvant presentation to promote
long-lived, protective adaptive immune memory responses [47].
Different adjuvants have already proven their potential for
(Sabin) IPV though via the parenteral route. However, limited
data are available on preclinical evaluation of adjuvants for
mucosal vaccination. The E. coli heat-labile toxin, with two
mutants (dmLT), has proven its potential for IPV delivery via
the mucosal route (sublingual) preclinically and an ongoing
clinical phase 1 study in healthy subjects should proof its
safety via the sublingual route (study nr. NCT02052934). This
could be therefore an interesting adjuvant for further devel-
opment for polio vaccination via the oral mucosa.
Special attention should be given to restrictions related to
the final target population for polio vaccination: infants. The
delivery method and the delivery device and formulation
should be suitable for application in infants. For example,
sublingual tablets are not suitable for infants since they may
give risk of choking. Improved ways of delivery to the buccal
and/or sublingual mucosa are under way. These include stick-
ing formulations, like fluids that jellify upon contact with the
mucosa (temperature) or thin films that can be applied below
the tongue. Advantage of these formulations is that they pro-
long the contact time with the mucosa and thereby may
decrease the dose needed for induction of immunity.
Dermal delivery might be a more suitable alternative for
vaccination of infants. A disadvantage of dermal delivery is
that in general no mucosal immunity is elicited by this route.
However, for certain vaccine adjuvant, like dmLT, combina-
tions there is evidence that ID vaccination may also have the
potential of inducing mucosal immunity [71–74]. New
approaches, such as biodegradable or coated microneedles,
hold promise for dermal delivery since they also may contri-
bute to the stability of the vaccine.
Five-year view
In the next 5 years, the phased withdrawal of OPV and inclu-
sion of IPV into all global routine immunization programs will
create a market for non-invasive delivery of polio vaccines,
although it is not clear how large this market will be, since IPV
demand in the post-eradication era is uncertain. However,
several new approaches for IPV delivery are underway. In
addition, potentially safer OPV vaccines may be introduced
to have a role during polio outbreaks.
Since more research groups have access to (Sabin) IPV via
support from organizations, such as BMGF and/or (new) sIPV
producers, more efforts to develop alternative administration
methods for IPV are expected in the coming years. This will
result in an increase of preclinical studies evaluating use of
new ways of delivery, which in 5 years may reach the clinical
development phase.
Furthermore, it is expected that other novel approaches,
such as heterogeneous prime-boost schedules, for example
priming with OPV and follow-up vaccinations with IM or der-
mal administered IPV will get attention the coming years. IPV
has been shown to boost mucosal immunity among recipients
who have earlier received OPV [75,76]. Further clinical studies
on heterogeneous prime-boost vaccination schedules, but
also of other administration strategies, mucosal immunity
will be more and better addressed by modern techniques [77].
Finally, the design of administration methods that have the
potential to give improved thermostability of the vaccine will
evolve, such as solid dosage forms for sublingual delivery [62],
dissolvable microneedle patches, and biodegradable mini-
implants (e.g. Bioneedles). These approaches would be favor-
able to reach remote areas in developing countries for which
proper logistics are not available.
One of the main challenges for future introduction of newly
administered IPV vaccines is the acceptance by the (final) stake-
holders, which include (local) governments shaping their immu-
nization programs, global vaccine procurement organizations
like UNICEF, but also key opinion leaders, vaccine producers,
and vaccine recipients. To this extent, BMGF, PATH, and WHO
are working as part of the Global Vaccine Action Plan on a
method to address total system cost-effectiveness [78]. A total
system cost-effectiveness evaluation is a holistic evaluation of
trade-offs between price and deliverability that potentially can
guide target product profiles and incentive structures that are
most representative of what countries need to efficiently
achieve maximum immunization coverage [78]. For instance,
this involves improved effectiveness of the vaccine for example
by mucosal immunity, advantages of logistics without use a
cold-chain, but also use of less-trained health-care personnel
and the costs of the vaccine. These types of approaches may
on the long term yield insights that for example a thermostable
IPV delivered by sublingual patches may come out favorable for
total system effectiveness and costs, while the primary cost price
of the novel vaccine might be relative high.
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Key issues
● To date, the potential of alternative IPV delivery has not
been explored comprehensively. Emphasis is on dermal
delivery and jet injection without the use of adjuvants.
● IPV has been shown to boost mucosal immunity among
recipients who have earlier received OPV, indicating that
heterologous vaccination strategies hold promise including
those with new(ly developed) delivery methods.
● Ideally, the new generation of IPV vaccines after global OPV
cessation, should induce mucosal immunity already after
prime immunization in order to stop the transmission of
polioviruses in high-risk areas.
● Future (pre-)clinical studies have to evaluate mucosal
immunity more extensively.
● Costs for novel ways of IPV delivery have to be approached
comprehensively in order to calculate cost-effectiveness
and warrant the product cost price, which are required for
market introduction.
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